Odyssey Therapeutics Reports Positive Clinical Proof-of-Concept for Lead Candidate OD-001 and Strong Cash Runway
ODTX sits 16% above its 52-week low of $16.
Summary
Odyssey Therapeutics reported strong clinical proof-of-concept data for its lead drug candidate, OD-001, in ulcerative colitis, alongside a healthy cash balance expected to fund operations into late 2028.
Key Events · Product Development and Regulatory · ODTX
-
Positive Clinical Proof-of-Concept for OD-001
Lead candidate OD-001 achieved clinical proof-of-concept in a Phase 2a trial for moderate to severe ulcerative colitis, showing 27% clinical remission and 61% clinical response. The drug was well tolerated.
-
Extended Cash Runway
The company reported a pro-forma cash position of $464.4 million as of March 31, 2026, which is expected to fund operations into the second half of 2028.
-
Q1 2026 Financial Results
Reported a net loss of $38.3 million for the first quarter ended March 31, 2026, with R&D expenses at $32.3 million.
-
Upcoming Clinical Milestones
Plans to initiate Phase 2b monotherapy and Phase 2a combination trials for OD-001 in H2 2026, with topline data expected in H2 2027. Also plans to file a CTA for OD-002 in H2 2026.
Analysis · ODTX · Life Sciences
Odyssey Therapeutics announced positive clinical proof-of-concept data for its lead candidate, OD-001, in a Phase 2a trial for ulcerative colitis. This de-risks the program significantly, showing efficacy with 27% clinical remission and 61% clinical response. The company also reported a robust cash position of $464.4 million, extending its operational runway into the second half of 2028, which provides financial stability for advancing its pipeline.
At the time of this filing, ODTX was trading at $18.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $871.8M. The 52-week trading range was $16.00 to $18.72. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.